Lineage Cell Therapeutics, Inc.
LCTX
$1.11
$0.032.78%
AMEX
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -38.03% | -73.90% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -38.03% | -73.90% | |||
| Cost of Revenue | 12.75% | -49.01% | |||
| Gross Profit | -372.58% | 53.77% | |||
| SG&A Expenses | 2.64% | 4.78% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 7.23% | -29.17% | |||
| Operating Income | -17.52% | -15.96% | |||
| Income Before Tax | 132.24% | -9.14% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 132.24% | -636.88% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -169.57% | 43.90% | |||
| Net Income | 130.80% | -665.45% | |||
| EBIT | -17.52% | -15.96% | |||
| EBITDA | -17.97% | -16.39% | |||
| EPS Basic | 130.10% | -644.44% | |||
| Normalized Basic EPS | 129.03% | -5.98% | |||
| EPS Diluted | -1.33% | -933.33% | |||
| Normalized Diluted EPS | 130.17% | 0.85% | |||
| Average Basic Shares Outstanding | 1.82% | 3.31% | |||
| Average Diluted Shares Outstanding | 0.11% | 10.12% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||